Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand. (28th November 2015)

• Record Type: Journal Article
• Authors: Lallemant, Marc; Le Coeur, Sophie; Sirirungsi, Wasna; Cressey, Tim R.; Ngo-Giang-Huong, Nicole; Traisathit, Patrinee; Klinbuayaem, Virat; Sabsanong, Prapan; Kanjanavikai, Prateep; Jourdain, Gonzague; Mcintosh, Kenneth; Koetsawang, Suporn
• Is Part Of: AIDS. Volume 29:Number 18(2015)
• Publication Date: 2015-11-28
• Subjects: antiretroviral therapy -- clinical trial -- HIV -- prevention of mother-to-child transmission -- Thailand; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000000865
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Objectives: Perinatal single-dose nevirapine (sdNVP) selects for resistance mutations. The objective of this trial was to compare two maternal sdNVP-sparing regimens with standard zidovudine (ZDV)/sdNVP prophylaxis. Design: PHPT-5 was a randomized, partially double-blind placebo-controlled, noninferiority trial in Thailand (NCT00409591). Study participants were women with CD4 + of at least 250 cells/μl and their infants. Methods: All women received ZDV from 28 weeks' gestation and their newborn infants for one week. Women were also randomized to receive NVP-NVP (reference): maternal intrapartum sdNVP with a 7-day 'tail' of ZDV along with lamivudine, and infant NVP (one dose immediately, another 48 h later); infant-only NVP: maternal placebos for sdNVP and the 'tail', with infant NVP; LPV/r: maternal LPV/r starting at 28 weeks. Infants were formula-fed. HIV-diagnosis was determined by DNA-PCR. Results: Four-hundred and thirty-five women were randomized between January 2009 and September 2010. Accrual was terminated prematurely following a change in Thai guidelines recommending antiretroviral combination therapy for all pregnant women. Data on 405 mothers and 407 live-born children were analyzed. Baseline characteristics were similar between arms. Intent-to-treat transmission rates were 3.8% (95% confidence interval: 1.2–8.6) in NVP-NVP, 1.6% (0.2–5.6) in infant-only NVP, and 1.4% (0.4–5.1) in LPV/r arms. As-treated rates were 2.2% (0.5–6.4), 3.2% (0.9–7.9), and 1.5% (0.2–5.2), respectively. Factors independently associated with transmission were prophylaxis duration less than 8 weeks (adjusted odds ratio 15.5; 3.6–66.1) and viral load at baseline at least 4 log10 copies/ml (adjusted odds ratio 10.9; 1.3–91.5). Regimens appeared well tolerated. Conclusion: Transmission rates in all arms were low but noninferiority was not proven. Antiretroviral prophylaxis for at least 8 weeks before delivery is necessary to minimize transmission risk.